Lake Forest, CA, May 26, 2015 - Cryoport, Inc. (OTCBB: CYRXD) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company is supporting South Mountain Pet Care (“SMPC”) with cryogenic logistics solutions for its canine reproduction business.
South Mountain Pet Care and Canine Reproduction Center, based in Draper, UT, provides canine reproduction services in addition to operating a veterinary clinic and animal hospital. They provide leading edge technology to support canine reproduction as well as general animal health. SMPC employs a team of licensed and experienced veterinarians that are dedicated to maintaining the health and wellness of pets.
Cryoport’s best-in-class cold chain logistics solutions will support the cryogenic shipment demands from South Mountain Pet Care’s canine reproduction business. Cryoport’s technology-driven chain of command capabilities will ensure the integrity of the specimen is maintained throughout the entire shipment process. The Company’s validated cryogenic solutions also provide global access that can attract geographically diverse customers seeking canine reproduction services from SMPC.
Carl L. Pew, DVM, MRCVS, Chief of Staff and Director of Reproduction Services at South Mountain Pet Care, commented, “We offer a wide array of services at South Mountain Pet Care that are supplemented with the latest advances in veterinarian technology. Our partnership with Cryoport furthers that focus as they provide our canine reproduction business with their best-in-class cryogenic logistics solutions. With the support of Cryoport, we can ensure our clients that their specimen is safe and secure throughout the entire reproduction process.”
Mr. Jerrell Shelton, Cryoport’s Chief Executive Officer, stated, “We are excited to work with South Mountain Pet Care to advance their canine breeding services. Cryoport is proud to support an organization that is committed to animal health and client service. This partnership further demonstrates the rapid expansion Cryoport is experiencing as we introduce our cryogenic shipping services to a number of new and growing industries.”
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.Investor Contacts:
Todd Fromer / Garth Russell
email@example.com / firstname.lastname@example.org
P: 1 212-682-6300